Progenics Finds New Partner For Relistor In Salix
This article was originally published in The Pink Sheet Daily
Executive Summary
A casualty of the Pfizer/Wyeth merger, Relistor rights bring Progenics $60 million upfront plus up to $290 million in milestones plus royalties.